inhibition of prostatic growth factor interaction, inhibition of
sodium and potassium-adenosine triphosphate in the prostate,
which results in the suppression of prostate cell metabolism and
growth and modulation of binding of sex hormone-binding globulin
to its receptor on prostate cell membranes
prostatic hyperplasia (BPH) is the most common non-neoplastic
disorder of aging in men. The prevalence of BPH is8% in men between 31 and 40 years of age and 50% in men
between 51 and 60 years of age.
approach to the treatment of BPH by alteration of cholesterol
metabolism, anti-oestrogenic, anti-androgenic (including
5a-reductase inhibitor activity), antiinflammatory effects, and
a decrease in available sex hormone binding globulin.
alternative to existing option that is devoid of adverse events
such as depression